Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)(COMPLETED)

This study has been completed.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by:
Schering-Plough
ClinicalTrials.gov Identifier:
NCT00652327
First received: March 31, 2008
Last updated: June 24, 2010
Last verified: June 2010

March 31, 2008
June 24, 2010
December 2005
July 2007   (final data collection date for primary outcome measure)
Percentage Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline at Study Endpoint, After 8 Weeks of Treatment [ Time Frame: Assessed at the end of 8 weeks of treatment (from baseline to endpoint) ] [ Designated as safety issue: No ]
Compare effect of ezetimibe 10 mg added to on-going statin with doubling the dose of statin on LDL-C [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00652327 on ClinicalTrials.gov Archive Site
Not Provided
  • Compare effect of ezetimibe 10 mg added to on-going statin with doubling the dose of statin on total cholesterol, triglycerides, and HDL-C. [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Compare proportions of patients achieving LDL-C targets with ezetimibe 10 mg added on to on-going statins therapy with doubling the dose of statin. [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Evaluate safety and tolerability of ezetimibe 10 mg added to on-going statins. [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)(COMPLETED)
A Multicenter, Randomized, Open-labeled, Parallel Group Comparison Study to Evaluate the Efficacy, Safety and Tolerability of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Ongoing Statin in the Treatment of Hypercholesterolemia.

This is a randomized, open label, parallel group comparison study. Following a 1-week screening period, patients will be randomized to 1 of 2 treatment groups: ezetimibe added to ongoing statin treatment (ezetimibe plus simvastatin, atorvastatin or pravastatin at doses of 10/20, 10/10 or 10/20 mg), or doubling the dose of ongoing statin (simvastatin 40 mg, atorvastatin 20 mg, or pravastatin 40 mg). Study drug will be administered once daily in the evening for 8 weeks. Patients will be instructed to follow a National Cholesterol Education Program (NCEP) or similar cholesterol-lowering dietary regimen throughout the study.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Hypercholesterolemia
  • Drug: Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)
    ezetimibe 10 mg plus ongoing statin (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) once daily for 8 weeks
  • Drug: Double Statin (simvastatin, atorvastatin, or pravastatin)
    simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks
  • Experimental: Ezetimibe + Statin
    Intervention: Drug: Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)
  • Active Comparator: Double Statin
    Intervention: Drug: Double Statin (simvastatin, atorvastatin, or pravastatin)
Yu CC, Lai WT, Shih KC, Lin TH, Lu CH, Lai HJ, Hanson ME, Hwang JJ. Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial. BMC Res Notes. 2012 May 23;5:251. doi: 10.1186/1756-0500-5-251.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
83
July 2007
July 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

80-120 patients will be recruited in this study. All patients must meet the following criteria and follow an NCEP or similar cholesterol-lowering dietary regimen throughout the study:

  • Men or women ≧18 and ≦80 years of age (Female patients receiving hormone therapy [including hormone replacement therapy, and estrogen antagonist/agonist, or oral contraceptives] and maintained on a stable dose and regimen for at least 8 weeks prior to visit 1 must be willing to continue the same regimen throughout the study. Females of childbearing potential must be using a medically acceptable method of birth control).
  • Willing to follow an NCEP Therapeutic Lifestyle Changes (TLC) or similar cholesterol-lowering diet for the duration of the study.
  • Patients with hypercholesterolemia who cannot achieve the optimal therapeutic goal with previous statin treatment (simvastatin 20 mg, atorvastatin 10 mg or pravastatin 20 mg alone for at least 12 weeks) will be enrolled into study. The treatment goal in primary prevention is LDL-C <160 mg/dL or LDL-C <130 mg/dL patient with ≧ 2 risk factors (risk factors: hypertension, male ≧ 45 years old, family of premature coronary artery disease [CAD], female ≧ 55 years old or menopause without hormone replace therapy, smoking); LDL-C ≤ 100 mg/dL in CAD patients (documented by coronary angiogram, positive treadmill test or thallium scan), or diabetes mellitus (DM) patients (Ante Cibum [AC][fasting plasma glucose] >126 mg/dL, Post Cibum [PC] [oral glucose tolerance test] > 200 mg/dL, World Health Organization criteria), ischemic stroke (neurological dysfunction with documented diagnosis with computed tomography [CT] or magnetic resonance imaging [MRI]), peripheral artery disease.
  • Triglyceride (TG) concentrations ≦ 400 mg/dL.
  • Liver transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) ≦ 2 x upper limit of normal (ULN) with no active liver disease and creatine kinase (CK) ≦ 2 x ULN at screen visit.

Exclusion Criteria:

The following conditions preclude patients from entry into this study:

  • Women who are pregnant or lactating.
  • History of mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled and stable on pharmacotherapy
  • Patients who have been treated with any other investigational drug within 3 months of visit 1.
  • Patients previously randomized to a study with ezetimibe.
  • Active liver disease or Impaired liver function tests (ALT, AST > 2xULN).
  • Impaired renal function ( serum creatinine ≧1.5 mg/dL) or nephrotic syndrome at visit 1
  • Unstable angina
  • Acute myocardial infarction, coronary bypass surgery within the previous six months of visit 1.
  • Uncontrolled cardiac arrhythmias
  • Uncontrolled hypertension (treated or untreated) with systolic blood pressure > 160 mmHg or diastolic > 100 mmHg at visit 1.
  • Poorly controlled diabetes mellitus patient (Patients who are under insulin injection and HbA1c>10.0%). If the patient is treated with medication for diabetes, the medication will be unchanged during the study period.
  • Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoprotein, e.g. hypothyroidism (thyroid-stimulating hormone [TSH] > 5.5 uIU/mL). However, patients who are on a stable therapy of thyroid replacement therapy for at least 6 weeks are eligible for enrollment.
  • Patients hypersensitive to HMG-CoA reductase inhibitors or ezetimibe.
  • Patient who is unable to give informed consent (the patient with a legal representative to sign the informed consent is eligible to participate the study).
  • Any condition or situation which, in the opinion of the investigator, might pose a risk to the patient or confound the results of the study.
  • Prohibited concomitant therapies.

    • Medications that are potent inhibitors of CYP3A4, including cyclosporine, systemic itraconazole or ketoconazole, erythromycin or clarithromycin, nefazodone, verapamil and human immunodeficiency virus (HIV) protease inhibitors.
    • Lipid-lowering agents including fish oils, Cholestin, bile-acid sequestrants, and niacin (<200 mg/day) taken within 6 weeks and fibrates taken within 8 weeks prior to enrollment.
    • Oral corticosteroids unless used as replacement therapy for pituitary/adrenal disease and treated with a stable regimen for at least 6 weeks prior to enrollment.
    • Treatment with psylium, other fiber-based laxatives, and/or over-the-counter (OTC) therapies known to affect serum lipid levels, phytosterol margarines, unless treated with a stable regimen for at least 6 weeks prior to enrollment, and patient agrees to remain on constant regimen for the duration of the study.
  • Patient is consuming > 250 ml of grapefruit juice per day.
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00652327
P04355
No
Head, Clinical Trials Registry & Results Disclosure Group, Schering-Plough
Schering-Plough
Merck Sharp & Dohme Corp.
Not Provided
Schering-Plough
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP